Cerebrospinal fluid lymphocytosis: a hallmark of neurological complications during checkpoint inhibition

Eur J Cancer. 2019 Nov:121:1-3. doi: 10.1016/j.ejca.2019.08.004. Epub 2019 Sep 12.

Authors

Erwin H J Tonk¹, Tom J Snijders², José J Koldenhof¹, Anne S R van Lindert³, Karijn P M Suijkerbuijk⁴

Affiliations

¹ Department of Medical Oncology, University Medical Center Utrecht Cancer Center, Heidelberglaan 100, 3584 CX Utrecht, the Netherlands.
² Brain Center Rudolf Magnus, Department of Neurology & Neurosurgery, Heidelberglaan 100, 3584 CX Utrecht, the Netherlands.
³ Department of Pulmonology, University Medical Center Utrecht Cancer Center, Heidelberglaan 100, 3584 CX Utrecht, the Netherlands.
⁴ Department of Medical Oncology, University Medical Center Utrecht Cancer Center, Heidelberglaan 100, 3584 CX Utrecht, the Netherlands. Electronic address: K.Suijkerbuijk@umcutrecht.nl.

PMID: 31522128
DOI: 10.1016/j.ejca.2019.08.004

No abstract available

Publication types

Case Reports
Letter

MeSH terms

Adult
Aged
Antibodies, Monoclonal, Humanized / administration & dosage
Antibodies, Monoclonal, Humanized / adverse effects*
Antineoplastic Combined Chemotherapy Protocols / therapeutic use
Cell Cycle Checkpoints / drug effects
Cell Cycle Checkpoints / immunology
Female
Humans
Immunosuppressive Agents / adverse effects
Immunosuppressive Agents / therapeutic use
Ipilimumab / administration & dosage
Ipilimumab / adverse effects*
Lymphocytosis / cerebrospinal fluid*
Lymphocytosis / chemically induced*
Lymphocytosis / diagnosis
Male
Middle Aged
Neoplasms / cerebrospinal fluid
Neoplasms / drug therapy
Neoplasms / pathology
Nervous System Diseases / cerebrospinal fluid
Nervous System Diseases / chemically induced
Nervous System Diseases / diagnosis
Neurotoxicity Syndromes / cerebrospinal fluid
Neurotoxicity Syndromes / diagnosis*
Neurotoxicity Syndromes / etiology
Nivolumab / administration & dosage
Nivolumab / adverse effects*
Protein Kinase Inhibitors / adverse effects
Protein Kinase Inhibitors / therapeutic use
Retrospective Studies
Severity of Illness Index

Substances

Antibodies, Monoclonal, Humanized
Immunosuppressive Agents
Ipilimumab
Protein Kinase Inhibitors
Nivolumab
pembrolizumab